1804 related articles for article (PubMed ID: 29532693)
1. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
2. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
[TBL] [Abstract][Full Text] [Related]
6. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
7. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of emerging immunotherapies in psoriasis.
Yiu ZZ; Warren RB
Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
[TBL] [Abstract][Full Text] [Related]
9. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
[TBL] [Abstract][Full Text] [Related]
10. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
[TBL] [Abstract][Full Text] [Related]
11. New and emerging therapies in psoriasis.
Leonardi CL; Gordon KB
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
[TBL] [Abstract][Full Text] [Related]
12. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
13. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
14. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593
[TBL] [Abstract][Full Text] [Related]
15. Biologics for Psoriasis.
Wride AM; Chen GF; Spaulding SL; Tkachenko E; Cohen JM
Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
[TBL] [Abstract][Full Text] [Related]
17. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
[TBL] [Abstract][Full Text] [Related]
19. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
Al-Salama ZT; Scott LJ
Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
